HER2/VEGF bispecific antibodies (Genentech)

N/A

Report date: 2025/02/01 20:00:06

Base Information

Drug NameHER2/VEGF bispecific antibodies (Genentech)

Drug Alias Namedual-specific monoclonal antibodies (Genentech)bH1-44DAF-3

ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Multispecific monoclonal antibody > Bispecific monoclonal antibody

Mechanisms of ActionReceptor tyrosine-protein kinase erbB-3 antagonistsVascular endothelial growth factor receptor antagonists

TargetsReceptor tyrosine-protein kinase erbB-3Vascular endothelial growth factor receptor

Therapy Area/IndicationsNeoplasms

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryUnited States

CombinationsNo

Global Highest StatusPending (Preclinical)

Highest Status in ChinaN/A

Originator CompaniesGenentech Inc

China Registration ClassN/A

Develop Information

Active CompaniesN/A

Inactive CompaniesGenentech Inc

Active IndicationsN/A

Inactive IndicationsNeoplasms

Other Information

ATC CodeN/A